{"gene":"ADRB1","run_date":"2026-06-09T22:02:42","timeline":{"discoveries":[{"year":2020,"finding":"GRK2 directly interacts with ADRB1 (demonstrated by in vitro co-immunoprecipitation), and this interaction mediates epinephrine-induced upregulation of hypertrophic/fibrotic genes and ADRB1 internalization in cardiomyocytes; genetic depletion of GRK2 blocks these effects. Paroxetine specifically blocks the GRK2-ADRB1 interaction, prevents ADRB1 internalization, and promotes ADRB1 sensitivity.","method":"Co-immunoprecipitation (direct interaction), genetic knockdown (GRK2 depletion), in vitro cardiomyocyte assays, in vivo spontaneously hypertensive rat model","journal":"Journal of the American Heart Association","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP establishing direct interaction, genetic depletion with defined phenotypic readout, and in vivo validation in a single lab with multiple orthogonal methods","pmids":["33372534"],"is_preprint":false},{"year":2015,"finding":"miR-19a suppresses ADRB1 expression by directly targeting the 3'UTR of ADRB1, as confirmed by AGO2 knockdown experiments and dual-luciferase reporter assay with western blot validation.","method":"AGO2 knockdown, 3'UTR luciferase reporter assay, western blot","journal":"International journal of clinical and experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — dual-luciferase and western blot in single lab, two orthogonal methods confirming direct miRNA-mediated repression","pmids":["25785039"],"is_preprint":false},{"year":2013,"finding":"The ADRB1 Arg389Gly polymorphism affects the early heart rate response to the β1AR antagonist esmolol: carriers of 0, 1, or 2 Arg389 alleles showed a gene-dose-dependent difference in esmolol inhibition of exercise-induced tachycardia in healthy individuals, with Arg389 homozygotes showing significantly greater inhibition than Gly389 homozygotes.","method":"Randomized pharmacodynamic crossover study in genotype-selected healthy volunteers; intravenous esmolol infusion with exercise challenge","journal":"Pharmacogenetics and genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — controlled pharmacodynamic study in genotype-stratified subjects, single lab, clear dose-response across three genotype groups","pmids":["23114278"],"is_preprint":false},{"year":2015,"finding":"The ADRB1 Arg389Gly polymorphism affects the hemodynamic response to dobutamine: Arg389Arg homozygotes showed a 4.7-fold greater resting heart rate response and a 3.9-fold greater renin response to dobutamine compared with Gly389Gly homozygotes in healthy individuals, demonstrating a gain-of-function effect of the Arg389 variant on β1AR agonist signaling.","method":"Controlled dobutamine infusion study in genotype-selected healthy individuals; heart rate, blood pressure, and plasma renin measured","journal":"Pharmacogenetics and genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — controlled pharmacodynamic study with multiple physiological readouts in genotype-stratified subjects, single lab","pmids":["26313487"],"is_preprint":false},{"year":2022,"finding":"FTO, an m6A demethylase, upregulates ADRB1 mRNA expression by reducing m6A modification on the ADRB1 transcript in rabbit preadipocytes, and ADRB1 itself inhibits adipocyte differentiation; FTO knockdown reduces ADRB1 expression while increasing m6A modification on ADRB1 mRNA.","method":"siRNA interference of FTO and ADRB1, oil red O staining, triglyceride assay, RT-qPCR, MeRIP-qPCR for m6A modification level","journal":"Animal biotechnology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MeRIP-qPCR directly measures m6A on ADRB1 transcript, loss-of-function for both FTO and ADRB1 with defined adipogenic phenotype, single lab","pmids":["35904284"],"is_preprint":false},{"year":2023,"finding":"ADRB1 on CaMKII-positive neurons in the medial prefrontal cortex (mPFC) mediates increased sensitivity to methamphetamine in male offspring of methamphetamine-exposed fathers: ADRB1 levels were elevated in mPFC of METH-sired offspring, and either pharmacological blockade (betaxolol) or virus-mediated knockdown of ADRB1 on CaMKII+ neurons suppressed subthreshold METH-evoked mPFC neuronal activation and conditioned place preference, with downstream p-ERK1/2 and ΔFosB as potential signals.","method":"Conditioned place preference, selective antagonist (betaxolol) microinfusion, viral knockdown of ADRB1 in CaMKII+ neurons, neuronal activity recording","journal":"Translational psychiatry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function via both pharmacology and virus-mediated knockdown with specific neuronal-population targeting and defined behavioral/cellular phenotype, single lab","pmids":["37857642"],"is_preprint":false},{"year":2024,"finding":"Differential CpG island methylation in the ADRB1 promoter region (lower methylation in cold-resistant Min pigs vs. DLY pigs) leads to higher ADRB1 expression in Min pig adipocytes, and overexpression of ADRB1 in DLY adipocytes enhances norepinephrine-induced browning (decreased adipogenesis markers, upregulated beige fat markers, increased mitochondrial biogenesis), while ADRB1 antagonist treatment in Min pig adipocytes reduces NE sensitivity.","method":"RT-qPCR, western blot, immunofluorescence, ADRB1 overexpression, ADRB1 antagonist treatment, promoter methylation analysis","journal":"Journal of thermal biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with defined thermogenic phenotype, promoter methylation analysis linking epigenetic regulation to expression, single lab with multiple methods","pmids":["38970835"],"is_preprint":false},{"year":2025,"finding":"Computational simulation (OneOPES enhanced sampling) of ADRB1 in apo and adrenaline-bound (holo) forms identified key water-mediated interactions and sodium ion/protonation-state-dependent microswitches that facilitate structural rearrangements required for ADRB1 activation; adrenaline binding promotes specific conformational transitions through these water networks.","method":"Multi-replica enhanced sampling molecular dynamics simulation (OneOPES); free energy landscape calculation","journal":"bioRxiv (preprint)","confidence":"Low","confidence_rationale":"Tier 4 / Weak — computational prediction only, no experimental validation reported in abstract","pmids":[],"is_preprint":true},{"year":2025,"finding":"CD4+ T cells can recognize the ADRB1 167-182 peptide presented on HLA-DRB1*13; stimulation with this peptide drives clonal expansion with a distinct TCR repertoire and CDR3 motif enriched in IFN-γ-producing cells. ADRB1-specific T cells in MI patients preferentially exhibit a memory phenotype, identifying ADRB1 as an autoantigen in cardiovascular disease.","method":"In vitro peptide stimulation of PBMCs, single-cell RNA/TCR-sequencing, HLA-tetramer staining, reporter cell line TCR validation, immunophenotyping of MI patient blood","journal":"bioRxiv (preprint)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — TCR specificity validated by HLA-tetramer and reporter cell line, multiple orthogonal methods, single lab preprint","pmids":[],"is_preprint":true},{"year":2025,"finding":"ADRB1 and ADRB2 N-terminus haplotypes that confer receptor internalization vs. internalization resistance regulate therapeutic responses to the biased ligand β-blocker bucindolol in heart failure: internalization-resistant haplotypes were associated with worse placebo outcomes but superior bucindolol response, and bucindolol (but not metoprolol) activated ERK1/2 signaling in isolated ventricular preparations with ≥3 internalization-resistant haplotypes, suggesting a biased ligand-dependent, internalization-associated cardioprotective ERK1/2 pathway.","method":"Clinical trial genetic substudy (ADRB1/ADRB2 haplotyping), Cox regression, ERK1/2 activation in isolated human heart preparations","journal":"bioRxiv (preprint)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ex vivo ERK1/2 activation in human heart preparations corroborates clinical haplotype-outcome data; multiple methods but preprint and single group","pmids":[],"is_preprint":true}],"current_model":"ADRB1 (β1-adrenergic receptor) is a GPCR that, upon activation by catecholamines, regulates heart rate, contractility, and renin release; its signaling is modulated by GRK2-mediated internalization (with paroxetine blocking the GRK2-ADRB1 interaction), post-transcriptionally repressed by miR-19a targeting its 3'UTR, epigenetically regulated by FTO-dependent m6A methylation on its transcript, and functionally influenced by common coding polymorphisms (notably Arg389Gly and Ser49Gly) that alter agonist-induced responses to both β-agonists and β-antagonists; in the brain, ADRB1 on CaMKII-positive mPFC neurons mediates adrenergic-driven neuronal activation and reward sensitization, and in adipocytes ADRB1 promotes norepinephrine-induced thermogenic browning."},"narrative":{"mechanistic_narrative":"ADRB1 is a catecholamine-responsive G-protein-coupled receptor whose adrenergic signaling drives tissue-specific physiological programs, from cardiac stress responses to adipocyte thermogenesis and central reward processing [PMID:33372534, PMID:37857642, PMID:38970835]. In cardiomyocytes, agonist-bound ADRB1 is engaged by GRK2 through a direct interaction that drives receptor internalization and epinephrine-induced expression of hypertrophic and fibrotic genes; depletion of GRK2 or pharmacological disruption of the GRK2-ADRB1 interaction by paroxetine prevents internalization and restores receptor sensitivity [PMID:33372534]. ADRB1 abundance is constrained at multiple regulatory layers: miR-19a directly targets the ADRB1 3'UTR to repress expression [PMID:25785039], FTO-dependent removal of m6A marks on the ADRB1 transcript raises its expression [PMID:35904284], and promoter CpG methylation tunes ADRB1 levels across tissues [PMID:38970835]. Functionally, FTO-driven ADRB1 inhibits adipocyte differentiation [PMID:35904284], while elevated ADRB1 promotes norepinephrine-induced browning of adipocytes through enhanced beige-fat marker expression and mitochondrial biogenesis [PMID:38970835]. Common coding polymorphisms gate signaling output: the Arg389 variant is a gain-of-function allele conferring greater agonist-driven heart rate and renin responses to dobutamine and greater antagonist inhibition by esmolol [PMID:23114278, PMID:26313487]. In the brain, ADRB1 on CaMKII-positive medial prefrontal cortex neurons mediates adrenergic neuronal activation and methamphetamine reward sensitization, with downstream p-ERK1/2 and ΔFosB signaling [PMID:37857642].","teleology":[{"year":2013,"claim":"Established that the common Arg389Gly coding variant alters the receptor's pharmacodynamic response to a β1AR antagonist in vivo, demonstrating that ADRB1 genotype shapes drug response.","evidence":"Randomized pharmacodynamic crossover study with esmolol infusion and exercise challenge in genotype-selected healthy volunteers","pmids":["23114278"],"confidence":"Medium","gaps":["Does not resolve the molecular basis of the altered antagonist sensitivity at the receptor level","Limited to acute heart rate readout in healthy subjects"]},{"year":2015,"claim":"Defined a post-transcriptional brake on ADRB1 by showing miR-19a directly represses the receptor via its 3'UTR, adding a layer of expression control beyond ligand-driven signaling.","evidence":"AGO2 knockdown, 3'UTR dual-luciferase reporter assay, and western blot","pmids":["25785039"],"confidence":"Medium","gaps":["Physiological context where miR-19a regulates ADRB1 not defined","No in vivo validation of the repression"]},{"year":2015,"claim":"Extended the Arg389Gly variant's impact to agonist signaling, establishing Arg389 as a gain-of-function allele for both chronotropic and renin responses.","evidence":"Controlled dobutamine infusion in genotype-selected individuals with heart rate, blood pressure, and plasma renin measurements","pmids":["26313487"],"confidence":"Medium","gaps":["Receptor-level mechanism of enhanced signaling not directly measured","Effect sizes from healthy subjects may not translate to disease states"]},{"year":2020,"claim":"Identified GRK2 as a direct ADRB1 interactor controlling receptor internalization and pathological cardiac gene expression, and showed paroxetine can pharmacologically block this interaction to preserve receptor sensitivity.","evidence":"Co-immunoprecipitation, GRK2 genetic knockdown, in vitro cardiomyocyte assays, and an in vivo spontaneously hypertensive rat model","pmids":["33372534"],"confidence":"High","gaps":["Structural basis of the GRK2-ADRB1 interface not resolved","Whether paroxetine's effect is specific to cardiac contexts not established"]},{"year":2022,"claim":"Linked m6A epigenetic marking to ADRB1 expression by showing FTO demethylase activity raises ADRB1 mRNA, and placed ADRB1 as a brake on adipocyte differentiation.","evidence":"siRNA knockdown of FTO and ADRB1, MeRIP-qPCR for m6A, oil red O staining, and triglyceride assays in rabbit preadipocytes","pmids":["35904284"],"confidence":"Medium","gaps":["Specific m6A reader interpreting the mark on ADRB1 mRNA not identified","Demonstrated in rabbit cells; human relevance not tested"]},{"year":2023,"claim":"Assigned a central nervous system role to ADRB1 by showing receptor on CaMKII+ mPFC neurons mediates methamphetamine reward sensitization through adrenergic neuronal activation.","evidence":"Conditioned place preference, betaxolol microinfusion, viral knockdown of ADRB1 in CaMKII+ neurons, and neuronal activity recording in METH-sired offspring","pmids":["37857642"],"confidence":"Medium","gaps":["Causal role of p-ERK1/2 and ΔFosB downstream signals not definitively established","Restricted to a paternal methamphetamine-exposure model"]},{"year":2024,"claim":"Connected promoter CpG methylation to ADRB1 expression differences and demonstrated ADRB1 promotes norepinephrine-induced adipocyte browning, framing it as an effector of thermogenic adaptation.","evidence":"Promoter methylation analysis, ADRB1 overexpression and antagonist treatment, beige-fat marker and mitochondrial biogenesis readouts in Min vs. DLY pig adipocytes","pmids":["38970835"],"confidence":"Medium","gaps":["Mechanism coupling ADRB1 signaling to mitochondrial biogenesis not detailed","Demonstrated in pig adipocytes"]},{"year":2025,"claim":"Proposed an atomic mechanism for ADRB1 activation in which water-mediated networks and sodium/protonation microswitches enable agonist-driven conformational transitions.","evidence":"Multi-replica OneOPES enhanced sampling molecular dynamics of apo and adrenaline-bound ADRB1 (preprint)","pmids":[],"confidence":"Low","gaps":["Computational prediction only, no experimental validation reported","Functional consequences of the proposed microswitches not tested"]},{"year":2025,"claim":"Identified ADRB1 as a candidate autoantigen by showing CD4+ T cells recognize an ADRB1 peptide on HLA-DRB1*13 with a memory phenotype enriched in myocardial infarction patients.","evidence":"Peptide stimulation of PBMCs, single-cell RNA/TCR-seq, HLA-tetramer staining, and reporter cell TCR validation (preprint)","pmids":[],"confidence":"Medium","gaps":["Causal contribution of ADRB1-specific T cells to cardiovascular disease not established","Preprint, single group"]},{"year":2025,"claim":"Linked ADRB1/ADRB2 N-terminus internalization haplotypes to biased-ligand therapeutic response, proposing an internalization-associated cardioprotective ERK1/2 pathway selectively engaged by bucindolol.","evidence":"Clinical trial genetic substudy with Cox regression and ERK1/2 activation in isolated human ventricular preparations (preprint)","pmids":[],"confidence":"Medium","gaps":["Mechanistic link between internalization resistance and ERK1/2 activation not fully defined","Preprint, single group"]},{"year":null,"claim":"How the diverse regulatory inputs on ADRB1 (GRK2 internalization, miRNA and m6A control, promoter methylation, biased-ligand signaling) are integrated within a single cell type to determine receptor output remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No unified model coupling expression control to signaling bias","Tissue-specific integration of these layers not characterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,3,5]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,5]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,3,5]}],"complexes":[],"partners":["GRK2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P08588","full_name":"Beta-1 adrenergic receptor","aliases":["Beta-1 adrenoreceptor","Beta-1 adrenoceptor"],"length_aa":477,"mass_kda":51.2,"function":"G protein-coupled receptor for catecholamines that couples to G(s) proteins to activate adenylate cyclase and cAMP-dependent pathway (PubMed:10212248, PubMed:12391161, PubMed:15358775). Binds epinephrine and norepinephrine with approximately equal affinity (PubMed:33093660). Mediates the activation of Ras via binding with cAMP-dependent RAPGEF2 (PubMed:12391161). As part of the sympathetic nervous system, plays a role in the physiologic regulation of cardiac functions such as stimulation of cardiomyocyte contraction (PubMed:11052857). Also delivers proapoptotic signals in cardiomyocytes (By similarity). Involved in the regulation of sleep/wake behaviors (PubMed:11854867, PubMed:31473062)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P08588/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ADRB1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ADRB1","total_profiled":1310},"omim":[{"mim_id":"620261","title":"ENDOPLASMIC RETICULUM MEMBRANE PROTEIN COMPLEX, SUBUNIT 6; EMC6","url":"https://www.omim.org/entry/620261"},{"mim_id":"618591","title":"SHORT SLEEP, FAMILIAL NATURAL, 2; FNSS2","url":"https://www.omim.org/entry/618591"},{"mim_id":"617239","title":"MYASTHENIC SYNDROME, CONGENITAL, 21, PRESYNAPTIC; CMS21","url":"https://www.omim.org/entry/617239"},{"mim_id":"614397","title":"MAJOR FACILITATOR SUPERFAMILY DOMAIN-CONTAINING PROTEIN 2A; MFSD2A","url":"https://www.omim.org/entry/614397"},{"mim_id":"613219","title":"FASTING PLASMA GLUCOSE LEVEL QUANTITATIVE TRAIT LOCUS 2; FGQTL2","url":"https://www.omim.org/entry/613219"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"heart muscle","ntpm":20.3},{"tissue":"lung","ntpm":11.4},{"tissue":"placenta","ntpm":27.4}],"url":"https://www.proteinatlas.org/search/ADRB1"},"hgnc":{"alias_symbol":[],"prev_symbol":["ADRB1R"]},"alphafold":{"accession":"P08588","domains":[{"cath_id":"1.20.1070.10","chopping":"56-266_313-398","consensus_level":"high","plddt":92.5814,"start":56,"end":398}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P08588","model_url":"https://alphafold.ebi.ac.uk/files/AF-P08588-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P08588-F1-predicted_aligned_error_v6.png","plddt_mean":75.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ADRB1","jax_strain_url":"https://www.jax.org/strain/search?query=ADRB1"},"sequence":{"accession":"P08588","fasta_url":"https://rest.uniprot.org/uniprotkb/P08588.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P08588/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P08588"}},"corpus_meta":[{"pmid":"33372534","id":"PMC_33372534","title":"Paroxetine Attenuates Cardiac Hypertrophy Via Blocking GRK2 and ADRB1 Interaction in Hypertension.","date":"2020","source":"Journal of the American Heart Association","url":"https://pubmed.ncbi.nlm.nih.gov/33372534","citation_count":44,"is_preprint":false},{"pmid":"12032746","id":"PMC_12032746","title":"Association between obesity and a polymorphism in the beta(1)-adrenoceptor gene (Gly389Arg ADRB1) in Caucasian women.","date":"2002","source":"International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity","url":"https://pubmed.ncbi.nlm.nih.gov/12032746","citation_count":43,"is_preprint":false},{"pmid":"20643254","id":"PMC_20643254","title":"Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.","date":"2010","source":"The American journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/20643254","citation_count":41,"is_preprint":false},{"pmid":"16315032","id":"PMC_16315032","title":"Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study.","date":"2005","source":"European journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16315032","citation_count":30,"is_preprint":false},{"pmid":"25823457","id":"PMC_25823457","title":"Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to β-blocker therapy in hypertension.","date":"2015","source":"The Journal of international medical research","url":"https://pubmed.ncbi.nlm.nih.gov/25823457","citation_count":28,"is_preprint":false},{"pmid":"17335470","id":"PMC_17335470","title":"Studies of associations between the Arg389Gly polymorphism of the beta1-adrenergic receptor gene (ADRB1) and hypertension and obesity in 7677 Danish white subjects.","date":"2007","source":"Diabetic medicine : a journal of the British Diabetic Association","url":"https://pubmed.ncbi.nlm.nih.gov/17335470","citation_count":27,"is_preprint":false},{"pmid":"29549925","id":"PMC_29549925","title":"The Association of ADRB1 and CYP2D6 Polymorphisms With Antihypertensive Effects and Analysis of Their Contribution to Hypertension Risk.","date":"2017","source":"The American journal of the medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29549925","citation_count":21,"is_preprint":false},{"pmid":"18059082","id":"PMC_18059082","title":"Association of ADRB1 and UCP3 gene polymorphisms with insulin sensitivity but not obesity.","date":"2007","source":"Hormone research","url":"https://pubmed.ncbi.nlm.nih.gov/18059082","citation_count":20,"is_preprint":false},{"pmid":"25785039","id":"PMC_25785039","title":"MiR-19a overexpression contributes to heart failure through targeting ADRB1.","date":"2015","source":"International journal of clinical and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25785039","citation_count":17,"is_preprint":false},{"pmid":"17635183","id":"PMC_17635183","title":"Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension.","date":"2007","source":"Fundamental & clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17635183","citation_count":15,"is_preprint":false},{"pmid":"21375401","id":"PMC_21375401","title":"Haplotype structures of common variants of CYP2C8, CYP2C9, and ADRB1 genes in a South Indian population.","date":"2011","source":"Genetic testing and molecular biomarkers","url":"https://pubmed.ncbi.nlm.nih.gov/21375401","citation_count":13,"is_preprint":false},{"pmid":"25638254","id":"PMC_25638254","title":"Effects of GRK5 and ADRB1 polymorphisms influence on systolic heart failure.","date":"2015","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25638254","citation_count":12,"is_preprint":false},{"pmid":"32586526","id":"PMC_32586526","title":"Variants in ADRB1 and CYP2C9: Association with Response to Atenolol and Losartan in Marfan Syndrome.","date":"2020","source":"The Journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/32586526","citation_count":12,"is_preprint":false},{"pmid":"35987510","id":"PMC_35987510","title":"Expression of the β1-adrenergic receptor (ADRB1) gene in the myocardium and β-adrenergic reactivity of the body in patients with a history of myocardium infraction.","date":"2022","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/35987510","citation_count":8,"is_preprint":false},{"pmid":"40406147","id":"PMC_40406147","title":"Single-cell RNA sequencing reveals adrb1 as a sympathetic nerve-regulated immune checkpoint driving T cell exhaustion and impacting immunotherapy in esophageal squamous cell carcinoma.","date":"2025","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/40406147","citation_count":7,"is_preprint":false},{"pmid":"37952358","id":"PMC_37952358","title":"Genetic polymorphisms in ADRB1, ADRB2 and CYP2D6 genes and response to beta-blockers in patients with acute coronary syndrome.","date":"2023","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/37952358","citation_count":7,"is_preprint":false},{"pmid":"24749907","id":"PMC_24749907","title":"ADRB1 and ADBR2 gene polymorphisms and the ocular hypotensive response to topical betaxolol in healthy Mexican subjects.","date":"2014","source":"Current eye research","url":"https://pubmed.ncbi.nlm.nih.gov/24749907","citation_count":7,"is_preprint":false},{"pmid":"24371822","id":"PMC_24371822","title":"IRS1, TCF7L2, ADRB1, PPARG, and HHEX polymorphisms associated with atherogenic risk in Mexican population.","date":"2013","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/24371822","citation_count":7,"is_preprint":false},{"pmid":"33593484","id":"PMC_33593484","title":"The ADRB1 (Adrenoceptor Beta 1) and ADRB2 genes significantly co-express with commonly mutated genes in prostate cancer.","date":"2020","source":"Discovery medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33593484","citation_count":7,"is_preprint":false},{"pmid":"27108086","id":"PMC_27108086","title":"Multiplex SNaPshot-a new simple and efficient CYP2D6 and ADRB1 genotyping method.","date":"2016","source":"Human genomics","url":"https://pubmed.ncbi.nlm.nih.gov/27108086","citation_count":7,"is_preprint":false},{"pmid":"20581797","id":"PMC_20581797","title":"A pilot study of the pharmacodynamic impact of SSRI drug selection and beta-1 receptor genotype (ADRB1) on cardiac vital signs in depressed patients: a novel pharmacogenetic approach.","date":"2010","source":"Psychopharmacology bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/20581797","citation_count":7,"is_preprint":false},{"pmid":"20384459","id":"PMC_20384459","title":"Association of ADRB1 gene polymorphism with atrial fibrillation.","date":"2010","source":"Genetic testing and molecular biomarkers","url":"https://pubmed.ncbi.nlm.nih.gov/20384459","citation_count":7,"is_preprint":false},{"pmid":"23114278","id":"PMC_23114278","title":"The common Arg389gly ADRB1 polymorphism affects heart rate response to the ultra-short-acting β(1) adrenergic receptor antagonist esmolol in healthy individuals.","date":"2013","source":"Pharmacogenetics and genomics","url":"https://pubmed.ncbi.nlm.nih.gov/23114278","citation_count":7,"is_preprint":false},{"pmid":"26379972","id":"PMC_26379972","title":"Association of ADRB1 gene polymorphisms with pain sensitivity in a Chinese population.","date":"2015","source":"International journal of clinical and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26379972","citation_count":6,"is_preprint":false},{"pmid":"36897672","id":"PMC_36897672","title":"Genetic and phenotypic frequency distribution of ACE, ADRB1, AGTR1, CYP2C9*3, CYP2D6*10, CYP3A5*3, NPPA and factors associated with hypertension in Chinese Han hypertensive patients.","date":"2023","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36897672","citation_count":6,"is_preprint":false},{"pmid":"26313487","id":"PMC_26313487","title":"Effects of sex and the common ADRB1 389 genetic polymorphism on the hemodynamic response to dobutamine.","date":"2015","source":"Pharmacogenetics and genomics","url":"https://pubmed.ncbi.nlm.nih.gov/26313487","citation_count":6,"is_preprint":false},{"pmid":"37857642","id":"PMC_37857642","title":"Paternal methamphetamine exposure induces higher sensitivity to methamphetamine in male offspring through driving ADRB1 on CaMKII-positive neurons in mPFC.","date":"2023","source":"Translational psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/37857642","citation_count":6,"is_preprint":false},{"pmid":"38138160","id":"PMC_38138160","title":"Associations between Selected ADRB1 and CYP2D6 Gene Polymorphisms in Children with Ventricular and Supraventricular Arrhythmias.","date":"2023","source":"Medicina (Kaunas, Lithuania)","url":"https://pubmed.ncbi.nlm.nih.gov/38138160","citation_count":5,"is_preprint":false},{"pmid":"35904284","id":"PMC_35904284","title":"FTO promoted adipocyte differentiation by regulating ADRB1 gene through m6A modification in Hycole rabbits.","date":"2022","source":"Animal biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/35904284","citation_count":4,"is_preprint":false},{"pmid":"35903112","id":"PMC_35903112","title":"Cervical Cancer Imaging Features Associated With ADRB1 as a Risk Factor for Cerebral Neurovascular Metastases.","date":"2022","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/35903112","citation_count":4,"is_preprint":false},{"pmid":"27829563","id":"PMC_27829563","title":"A new sight for detecting the ADRB1 gene mutation to guide a therapeutic regimen for hypertension based on a CeO2-doped nanoprobe.","date":"2016","source":"Biosensors & bioelectronics","url":"https://pubmed.ncbi.nlm.nih.gov/27829563","citation_count":4,"is_preprint":false},{"pmid":"37736348","id":"PMC_37736348","title":"CYP2D6 and ADRB1 genetic polymorphisms and the selection of antihypertensive beta-receptor blockers for hypertensive patients.","date":"2023","source":"American journal of cardiovascular disease","url":"https://pubmed.ncbi.nlm.nih.gov/37736348","citation_count":3,"is_preprint":false},{"pmid":"29095089","id":"PMC_29095089","title":"Impact of CYP2D6 and ADRB1 polymorphisms on heart rate of post-PCI patients treated with metoprolol.","date":"2024","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/29095089","citation_count":3,"is_preprint":false},{"pmid":"29768300","id":"PMC_29768300","title":"The hemodynamic response to constant dobutamine infusion: the effect of ADRB1 389 polymorphism and sex.","date":"2018","source":"Pharmacogenetics and genomics","url":"https://pubmed.ncbi.nlm.nih.gov/29768300","citation_count":3,"is_preprint":false},{"pmid":"33572708","id":"PMC_33572708","title":"Association of Genetic Variances in ADRB1 and PPARGC1a with Two-Kilometre Running Time-Trial Performance in Australian Football League Players: A Preliminary Study.","date":"2021","source":"Sports (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/33572708","citation_count":3,"is_preprint":false},{"pmid":"21806475","id":"PMC_21806475","title":"ADRB1 as a potential target for gene therapy of pregnancy induced hypertension and gestational diabetes mellitus.","date":"2011","source":"Clinical and experimental hypertension (New York, N.Y. : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/21806475","citation_count":3,"is_preprint":false},{"pmid":"38144921","id":"PMC_38144921","title":"Non‑synonymous polymorphisms in the HRC and ADRB1 genes may be associated with all‑cause death in patients with non‑ischemic heart failure.","date":"2023","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38144921","citation_count":2,"is_preprint":false},{"pmid":"33451866","id":"PMC_33451866","title":"Influence of ADRB1, ADRB2, and COMT Genetic Polymorphisms on Postoperative Outcomes of Patients Undergoing Cardiac Valve Surgery.","date":"2021","source":"Clinical therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/33451866","citation_count":2,"is_preprint":false},{"pmid":"22760495","id":"PMC_22760495","title":"Effect of specific ADRB1/ADRB2/AGT genotype combinations on the association between survival and carvedilol treatment in chronic heart failure: a substudy of the ECHOS trial.","date":"2012","source":"Pharmacogenetics and genomics","url":"https://pubmed.ncbi.nlm.nih.gov/22760495","citation_count":2,"is_preprint":false},{"pmid":"19462935","id":"PMC_19462935","title":"Rapid detection of the R389G polymorphism of ADRB1 by real time PCR using fluorescence resonance energy transfer.","date":"2009","source":"Clinical laboratory","url":"https://pubmed.ncbi.nlm.nih.gov/19462935","citation_count":2,"is_preprint":false},{"pmid":"38970835","id":"PMC_38970835","title":"Differential expression of ADRB1 causes different responses to norepinephrine in adipocytes of Duroc-Landrace-Yorkshire pigs and min pigs.","date":"2024","source":"Journal of thermal biology","url":"https://pubmed.ncbi.nlm.nih.gov/38970835","citation_count":1,"is_preprint":false},{"pmid":"41491200","id":"PMC_41491200","title":"Reinvigorating CD8+ T cells through ADRB1 blockade using copper-propranolol nanoparticles for enhanced immune checkpoint blockade therapy.","date":"2026","source":"Journal of nanobiotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/41491200","citation_count":1,"is_preprint":false},{"pmid":"40548695","id":"PMC_40548695","title":"Caveolin 3 Variant T78M in a Large Family With Brugada Syndrome: Clinical Features and Coexistence of ADRB1 and GRK5 Gene Mutation.","date":"2025","source":"Journal of cardiovascular electrophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/40548695","citation_count":0,"is_preprint":false},{"pmid":"38682747","id":"PMC_38682747","title":"Assessment of ADRB1 polymorphism in patients with acute coronary syndrome treated with ticagrelor and aspirin.","date":"2024","source":"Personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38682747","citation_count":0,"is_preprint":false},{"pmid":"40441323","id":"PMC_40441323","title":"Investigating ADRB1 and ADRB3 polymorphisms as risk factors for type 2 diabetes: A retrospective study.","date":"2025","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/40441323","citation_count":0,"is_preprint":false},{"pmid":"39523089","id":"PMC_39523089","title":"[Behavioral changes of transgenic mice carrying Adrb1-A187V mutation with short sleep duration under different dietary conditions].","date":"2024","source":"Nan fang yi ke da xue xue bao = Journal of Southern Medical University","url":"https://pubmed.ncbi.nlm.nih.gov/39523089","citation_count":0,"is_preprint":false},{"pmid":"37898944","id":"PMC_37898944","title":"THE ROLE OF LEFT VENTRICULAR HYPERTROPHY, RS1801253 AND RS1801252 ALLELIC POLYMORPHISMS OF ADRB1 IN ASSESSING THE RISK OF SUDDEN CARDIAC DEATH IN PATIENTS WITH ARTERIAL HYPERTENSION.","date":"2023","source":"Wiadomosci lekarskie (Warsaw, Poland : 1960)","url":"https://pubmed.ncbi.nlm.nih.gov/37898944","citation_count":0,"is_preprint":false},{"pmid":"31884750","id":"PMC_31884750","title":"[The role of ADRB1 genes polymorphism in examined patients with chronic rheumatic heart disease].","date":"2019","source":"Problemy sotsial'noi gigieny, zdravookhraneniia i istorii meditsiny","url":"https://pubmed.ncbi.nlm.nih.gov/31884750","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.10.17.683095","title":"Shared and reinforcer-specific alterations in the CRH and noradrenergic systems following short- and long-term withdrawal from cocaine, heroin, and sucrose self-administration","date":"2025-10-17","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.17.683095","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.08.22.25333921","title":"β<sub>1</sub>- and β<sub>2</sub>-adrenergic Receptor Haplotypes Regulate Therapeutic Responses to Placebo and the Biased Ligand β-blocker Bucindolol","date":"2025-08-24","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.22.25333921","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.06.05.25328514","title":"Tracking antigen-specific T cell responses in patients with myocardial infarction","date":"2025-06-06","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.05.25328514","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.03.03.641221","title":"Revealing Water-Mediated Activation Mechanisms in the Beta 1-Adrenergic Receptor via OneOPES-Enhanced Free Energy Landscapes","date":"2025-03-10","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.03.641221","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.04.11.25325641","title":"Repurposing drugs for the prevention of vascular dementia: Evidence from drug target Mendelian randomization","date":"2025-04-11","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.11.25325641","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.06.08.658488","title":"Random survival forests identify myocardial gene signatures associated with survival in heart failure with preserved ejection fraction","date":"2025-06-11","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.08.658488","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.03.17.643631","title":"Mechanisms of Activation and Serotonin release from Human Enterochromaffin Cells","date":"2025-03-17","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.17.643631","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.09.08.611829","title":"β2-Adrenergic Biased Agonist Nebivolol Inhibits the Development of Th17 and the Response of Memory Th17 Cells in an NF-κB-Dependent Manner","date":"2024-09-10","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.08.611829","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":35843,"output_tokens":2881,"usd":0.075372,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":10204,"output_tokens":3367,"usd":0.067598,"stage2_stop_reason":"end_turn"},"total_usd":0.14297,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2020,\n      \"finding\": \"GRK2 directly interacts with ADRB1 (demonstrated by in vitro co-immunoprecipitation), and this interaction mediates epinephrine-induced upregulation of hypertrophic/fibrotic genes and ADRB1 internalization in cardiomyocytes; genetic depletion of GRK2 blocks these effects. Paroxetine specifically blocks the GRK2-ADRB1 interaction, prevents ADRB1 internalization, and promotes ADRB1 sensitivity.\",\n      \"method\": \"Co-immunoprecipitation (direct interaction), genetic knockdown (GRK2 depletion), in vitro cardiomyocyte assays, in vivo spontaneously hypertensive rat model\",\n      \"journal\": \"Journal of the American Heart Association\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP establishing direct interaction, genetic depletion with defined phenotypic readout, and in vivo validation in a single lab with multiple orthogonal methods\",\n      \"pmids\": [\"33372534\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"miR-19a suppresses ADRB1 expression by directly targeting the 3'UTR of ADRB1, as confirmed by AGO2 knockdown experiments and dual-luciferase reporter assay with western blot validation.\",\n      \"method\": \"AGO2 knockdown, 3'UTR luciferase reporter assay, western blot\",\n      \"journal\": \"International journal of clinical and experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — dual-luciferase and western blot in single lab, two orthogonal methods confirming direct miRNA-mediated repression\",\n      \"pmids\": [\"25785039\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The ADRB1 Arg389Gly polymorphism affects the early heart rate response to the β1AR antagonist esmolol: carriers of 0, 1, or 2 Arg389 alleles showed a gene-dose-dependent difference in esmolol inhibition of exercise-induced tachycardia in healthy individuals, with Arg389 homozygotes showing significantly greater inhibition than Gly389 homozygotes.\",\n      \"method\": \"Randomized pharmacodynamic crossover study in genotype-selected healthy volunteers; intravenous esmolol infusion with exercise challenge\",\n      \"journal\": \"Pharmacogenetics and genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — controlled pharmacodynamic study in genotype-stratified subjects, single lab, clear dose-response across three genotype groups\",\n      \"pmids\": [\"23114278\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The ADRB1 Arg389Gly polymorphism affects the hemodynamic response to dobutamine: Arg389Arg homozygotes showed a 4.7-fold greater resting heart rate response and a 3.9-fold greater renin response to dobutamine compared with Gly389Gly homozygotes in healthy individuals, demonstrating a gain-of-function effect of the Arg389 variant on β1AR agonist signaling.\",\n      \"method\": \"Controlled dobutamine infusion study in genotype-selected healthy individuals; heart rate, blood pressure, and plasma renin measured\",\n      \"journal\": \"Pharmacogenetics and genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — controlled pharmacodynamic study with multiple physiological readouts in genotype-stratified subjects, single lab\",\n      \"pmids\": [\"26313487\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FTO, an m6A demethylase, upregulates ADRB1 mRNA expression by reducing m6A modification on the ADRB1 transcript in rabbit preadipocytes, and ADRB1 itself inhibits adipocyte differentiation; FTO knockdown reduces ADRB1 expression while increasing m6A modification on ADRB1 mRNA.\",\n      \"method\": \"siRNA interference of FTO and ADRB1, oil red O staining, triglyceride assay, RT-qPCR, MeRIP-qPCR for m6A modification level\",\n      \"journal\": \"Animal biotechnology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MeRIP-qPCR directly measures m6A on ADRB1 transcript, loss-of-function for both FTO and ADRB1 with defined adipogenic phenotype, single lab\",\n      \"pmids\": [\"35904284\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ADRB1 on CaMKII-positive neurons in the medial prefrontal cortex (mPFC) mediates increased sensitivity to methamphetamine in male offspring of methamphetamine-exposed fathers: ADRB1 levels were elevated in mPFC of METH-sired offspring, and either pharmacological blockade (betaxolol) or virus-mediated knockdown of ADRB1 on CaMKII+ neurons suppressed subthreshold METH-evoked mPFC neuronal activation and conditioned place preference, with downstream p-ERK1/2 and ΔFosB as potential signals.\",\n      \"method\": \"Conditioned place preference, selective antagonist (betaxolol) microinfusion, viral knockdown of ADRB1 in CaMKII+ neurons, neuronal activity recording\",\n      \"journal\": \"Translational psychiatry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function via both pharmacology and virus-mediated knockdown with specific neuronal-population targeting and defined behavioral/cellular phenotype, single lab\",\n      \"pmids\": [\"37857642\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Differential CpG island methylation in the ADRB1 promoter region (lower methylation in cold-resistant Min pigs vs. DLY pigs) leads to higher ADRB1 expression in Min pig adipocytes, and overexpression of ADRB1 in DLY adipocytes enhances norepinephrine-induced browning (decreased adipogenesis markers, upregulated beige fat markers, increased mitochondrial biogenesis), while ADRB1 antagonist treatment in Min pig adipocytes reduces NE sensitivity.\",\n      \"method\": \"RT-qPCR, western blot, immunofluorescence, ADRB1 overexpression, ADRB1 antagonist treatment, promoter methylation analysis\",\n      \"journal\": \"Journal of thermal biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with defined thermogenic phenotype, promoter methylation analysis linking epigenetic regulation to expression, single lab with multiple methods\",\n      \"pmids\": [\"38970835\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Computational simulation (OneOPES enhanced sampling) of ADRB1 in apo and adrenaline-bound (holo) forms identified key water-mediated interactions and sodium ion/protonation-state-dependent microswitches that facilitate structural rearrangements required for ADRB1 activation; adrenaline binding promotes specific conformational transitions through these water networks.\",\n      \"method\": \"Multi-replica enhanced sampling molecular dynamics simulation (OneOPES); free energy landscape calculation\",\n      \"journal\": \"bioRxiv (preprint)\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Weak — computational prediction only, no experimental validation reported in abstract\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CD4+ T cells can recognize the ADRB1 167-182 peptide presented on HLA-DRB1*13; stimulation with this peptide drives clonal expansion with a distinct TCR repertoire and CDR3 motif enriched in IFN-γ-producing cells. ADRB1-specific T cells in MI patients preferentially exhibit a memory phenotype, identifying ADRB1 as an autoantigen in cardiovascular disease.\",\n      \"method\": \"In vitro peptide stimulation of PBMCs, single-cell RNA/TCR-sequencing, HLA-tetramer staining, reporter cell line TCR validation, immunophenotyping of MI patient blood\",\n      \"journal\": \"bioRxiv (preprint)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — TCR specificity validated by HLA-tetramer and reporter cell line, multiple orthogonal methods, single lab preprint\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ADRB1 and ADRB2 N-terminus haplotypes that confer receptor internalization vs. internalization resistance regulate therapeutic responses to the biased ligand β-blocker bucindolol in heart failure: internalization-resistant haplotypes were associated with worse placebo outcomes but superior bucindolol response, and bucindolol (but not metoprolol) activated ERK1/2 signaling in isolated ventricular preparations with ≥3 internalization-resistant haplotypes, suggesting a biased ligand-dependent, internalization-associated cardioprotective ERK1/2 pathway.\",\n      \"method\": \"Clinical trial genetic substudy (ADRB1/ADRB2 haplotyping), Cox regression, ERK1/2 activation in isolated human heart preparations\",\n      \"journal\": \"bioRxiv (preprint)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ex vivo ERK1/2 activation in human heart preparations corroborates clinical haplotype-outcome data; multiple methods but preprint and single group\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"ADRB1 (β1-adrenergic receptor) is a GPCR that, upon activation by catecholamines, regulates heart rate, contractility, and renin release; its signaling is modulated by GRK2-mediated internalization (with paroxetine blocking the GRK2-ADRB1 interaction), post-transcriptionally repressed by miR-19a targeting its 3'UTR, epigenetically regulated by FTO-dependent m6A methylation on its transcript, and functionally influenced by common coding polymorphisms (notably Arg389Gly and Ser49Gly) that alter agonist-induced responses to both β-agonists and β-antagonists; in the brain, ADRB1 on CaMKII-positive mPFC neurons mediates adrenergic-driven neuronal activation and reward sensitization, and in adipocytes ADRB1 promotes norepinephrine-induced thermogenic browning.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ADRB1 is a catecholamine-responsive G-protein-coupled receptor whose adrenergic signaling drives tissue-specific physiological programs, from cardiac stress responses to adipocyte thermogenesis and central reward processing [#0, #5, #6]. In cardiomyocytes, agonist-bound ADRB1 is engaged by GRK2 through a direct interaction that drives receptor internalization and epinephrine-induced expression of hypertrophic and fibrotic genes; depletion of GRK2 or pharmacological disruption of the GRK2-ADRB1 interaction by paroxetine prevents internalization and restores receptor sensitivity [#0]. ADRB1 abundance is constrained at multiple regulatory layers: miR-19a directly targets the ADRB1 3'UTR to repress expression [#1], FTO-dependent removal of m6A marks on the ADRB1 transcript raises its expression [#4], and promoter CpG methylation tunes ADRB1 levels across tissues [#6]. Functionally, FTO-driven ADRB1 inhibits adipocyte differentiation [#4], while elevated ADRB1 promotes norepinephrine-induced browning of adipocytes through enhanced beige-fat marker expression and mitochondrial biogenesis [#6]. Common coding polymorphisms gate signaling output: the Arg389 variant is a gain-of-function allele conferring greater agonist-driven heart rate and renin responses to dobutamine and greater antagonist inhibition by esmolol [#2, #3]. In the brain, ADRB1 on CaMKII-positive medial prefrontal cortex neurons mediates adrenergic neuronal activation and methamphetamine reward sensitization, with downstream p-ERK1/2 and \\u0394FosB signaling [#5].\",\n  \"teleology\": [\n    {\n      \"year\": 2013,\n      \"claim\": \"Established that the common Arg389Gly coding variant alters the receptor's pharmacodynamic response to a \\u03b21AR antagonist in vivo, demonstrating that ADRB1 genotype shapes drug response.\",\n      \"evidence\": \"Randomized pharmacodynamic crossover study with esmolol infusion and exercise challenge in genotype-selected healthy volunteers\",\n      \"pmids\": [\"23114278\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not resolve the molecular basis of the altered antagonist sensitivity at the receptor level\", \"Limited to acute heart rate readout in healthy subjects\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined a post-transcriptional brake on ADRB1 by showing miR-19a directly represses the receptor via its 3'UTR, adding a layer of expression control beyond ligand-driven signaling.\",\n      \"evidence\": \"AGO2 knockdown, 3'UTR dual-luciferase reporter assay, and western blot\",\n      \"pmids\": [\"25785039\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological context where miR-19a regulates ADRB1 not defined\", \"No in vivo validation of the repression\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Extended the Arg389Gly variant's impact to agonist signaling, establishing Arg389 as a gain-of-function allele for both chronotropic and renin responses.\",\n      \"evidence\": \"Controlled dobutamine infusion in genotype-selected individuals with heart rate, blood pressure, and plasma renin measurements\",\n      \"pmids\": [\"26313487\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor-level mechanism of enhanced signaling not directly measured\", \"Effect sizes from healthy subjects may not translate to disease states\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified GRK2 as a direct ADRB1 interactor controlling receptor internalization and pathological cardiac gene expression, and showed paroxetine can pharmacologically block this interaction to preserve receptor sensitivity.\",\n      \"evidence\": \"Co-immunoprecipitation, GRK2 genetic knockdown, in vitro cardiomyocyte assays, and an in vivo spontaneously hypertensive rat model\",\n      \"pmids\": [\"33372534\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the GRK2-ADRB1 interface not resolved\", \"Whether paroxetine's effect is specific to cardiac contexts not established\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Linked m6A epigenetic marking to ADRB1 expression by showing FTO demethylase activity raises ADRB1 mRNA, and placed ADRB1 as a brake on adipocyte differentiation.\",\n      \"evidence\": \"siRNA knockdown of FTO and ADRB1, MeRIP-qPCR for m6A, oil red O staining, and triglyceride assays in rabbit preadipocytes\",\n      \"pmids\": [\"35904284\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific m6A reader interpreting the mark on ADRB1 mRNA not identified\", \"Demonstrated in rabbit cells; human relevance not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Assigned a central nervous system role to ADRB1 by showing receptor on CaMKII+ mPFC neurons mediates methamphetamine reward sensitization through adrenergic neuronal activation.\",\n      \"evidence\": \"Conditioned place preference, betaxolol microinfusion, viral knockdown of ADRB1 in CaMKII+ neurons, and neuronal activity recording in METH-sired offspring\",\n      \"pmids\": [\"37857642\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal role of p-ERK1/2 and \\u0394FosB downstream signals not definitively established\", \"Restricted to a paternal methamphetamine-exposure model\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Connected promoter CpG methylation to ADRB1 expression differences and demonstrated ADRB1 promotes norepinephrine-induced adipocyte browning, framing it as an effector of thermogenic adaptation.\",\n      \"evidence\": \"Promoter methylation analysis, ADRB1 overexpression and antagonist treatment, beige-fat marker and mitochondrial biogenesis readouts in Min vs. DLY pig adipocytes\",\n      \"pmids\": [\"38970835\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism coupling ADRB1 signaling to mitochondrial biogenesis not detailed\", \"Demonstrated in pig adipocytes\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Proposed an atomic mechanism for ADRB1 activation in which water-mediated networks and sodium/protonation microswitches enable agonist-driven conformational transitions.\",\n      \"evidence\": \"Multi-replica OneOPES enhanced sampling molecular dynamics of apo and adrenaline-bound ADRB1 (preprint)\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Computational prediction only, no experimental validation reported\", \"Functional consequences of the proposed microswitches not tested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified ADRB1 as a candidate autoantigen by showing CD4+ T cells recognize an ADRB1 peptide on HLA-DRB1*13 with a memory phenotype enriched in myocardial infarction patients.\",\n      \"evidence\": \"Peptide stimulation of PBMCs, single-cell RNA/TCR-seq, HLA-tetramer staining, and reporter cell TCR validation (preprint)\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal contribution of ADRB1-specific T cells to cardiovascular disease not established\", \"Preprint, single group\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Linked ADRB1/ADRB2 N-terminus internalization haplotypes to biased-ligand therapeutic response, proposing an internalization-associated cardioprotective ERK1/2 pathway selectively engaged by bucindolol.\",\n      \"evidence\": \"Clinical trial genetic substudy with Cox regression and ERK1/2 activation in isolated human ventricular preparations (preprint)\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanistic link between internalization resistance and ERK1/2 activation not fully defined\", \"Preprint, single group\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the diverse regulatory inputs on ADRB1 (GRK2 internalization, miRNA and m6A control, promoter methylation, biased-ligand signaling) are integrated within a single cell type to determine receptor output remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unified model coupling expression control to signaling bias\", \"Tissue-specific integration of these layers not characterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 3, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 3, 5]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"GRK2\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}